News
-
ONL Therapeutics closes $4.25 million in Series A funding
-
ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program
-
ONL Therapeutics Receives Phase II SBIR Grant from National Eye Institute for Development of Novel Retinal Disease Treatment
-
SBIR Award, $1M Investment Get ONL Therapeutics to Clinical Trials
-
Applications for Neuroprotection: The Next Therapeutic Category in Retina Medicine
-
ONL Therapeutics Wins Emerging Company Showcase at MichBio Expo
-
ONL ANNOUNCES LEADERSHIP CHANGES
-
ONL RECEIVES ORPHAN DRUG DESIGNATION FOR ONL-101 IN RETINAL DETACHMENT